January 6 th at11:50 am PT / 2:50 pm ET
HOW M&A SPURS INNOVATION
Mark Enyedy, CEO, ImmunoGen; Henry Ji, CEO, Sorrento Therapeutics;Rachna Khosla , SVP, BD, Amgen; Stuart Mackey, Global Head, BD, Daiichi Sankyo
Moderator: Chad Shear, Principal, Fish & Richardson
Conference information:
Longwood Healthcare Leaders meetings are invitation-only forums typically held at leading academic institutions. Biopharma CEOs, heads of R&D, academic researchers, and healthcare investors join off-the-record discussions that generate new company ideas and approaches for
About
Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates (“ADCs”), and oncolytic virus (“Seprehvec™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG™, COVISHIELD™, COVI-MSC™ and COVIDROPS™; and diagnostic test solutions, including COVITRACK™ and COVISTIX™.
Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia (PHN). RTX has cleared for Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients. SEMDEXA announced highly statistically significant positive top-line results from its Phase III Pivotal Trial C.L.E.A.R Program for its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica). ZTlido® was approved by the FDA on
For more information visit www.sorrentotherapeutics.com
Forward-Looking Statements
This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to
Media and Investor Relations
Contact:
Email: mediarelations@sorrentotherapeutics.com
Sorrento® and the Sorrento logo are registered trademarks of
G-MAB™, DAR-T™, Seprehvec™, SOFUSA™, COVI-AMG™, COVISHIELD™, COVIDROPS™, COVI-MSC™, COVITRACK™ and COVISTIX™ are trademarks of
SEMDEXA™ is a trademark of
ZTlido® is a registered trademark owned by
All other trademarks are the property of their respective owners.
©2022
![](https://ml.globenewswire.com/media/OWIxODcxMzUtZDNmNi00YWVlLThkMzktZjkyYjI1NDA3MTczLTEwNjE0MTU=/tiny/Sorrento-Therapeutics-Inc-.png)
2022 GlobeNewswire, Inc., source